The new Precision Medicine Initiative will require advances in our regulatory frameworks, especially for genomic testing. The FDA has been exploring radical new approaches, aiming to promote rapid innovation while ensuring safety and efficacy.
No takes yet. Share an insight, caveat, or question.
Eric S. Lander (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: